BRNS VS PBYI Stock Comparison

Performance

BRNS
10/100

BRNS returned -42.40% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

PBYI
100/100

PBYI returned 4.80% in the last 12 months. Based on SPY's performance of -21.18%, its performance is above average giving it a score of 100 of 100.

Earnings

BRNS
100/100

BRNS has missed earnings 1 times in the last 20 quarters.

PBYI
10/100

PBYI has missed earnings 6 times in the last 20 quarters.

Volatility

BRNS
50/100

BRNS has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

PBYI
48/100

PBYI has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

Analyst Price Targets

BRNS

"Analyst Price Targets" not found for BRNS

PBYI
83/100

9 analysts offer 12-month price targets for PBYI. Together, they have an average target of 0, the most optimistic target put PBYI at 0 within 12-months and the most pessimistic has PBYI at 0.

Sentiment

BRNS

"Sentiment" not found for BRNS

PBYI
65/100

PBYI had a bullish sentiment score of 65.49% across Twitter and StockTwits over the last 12 months. It had an average of 5.77 posts, 2.74 comments, and 4.22 likes per day.

Technicals

BRNS

"Technicals" not found for BRNS

PBYI
36/100

PBYI receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

Profit

BRNS

"Profit" not found for BRNS

PBYI
34/100

Out of the last 20 quarters, PBYI has had 6 profitable quarters and has increased their profits year over year on 5 of them.

All score calculations are broken down here to help you make more informed investing decisions

Barinthus Biotherapeutics plc American Depositary Shares Summary

Nasdaq / BRNS

Healthcare

Biotechnology

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

PUMA BIOTECHNOLOGY INC Summary

Nasdaq / PBYI

Healthcare

Biotechnology

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Power up your portfolio